For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $6.62 in the prior trading day, Revance Therapeutics Inc (NASDAQ: RVNC) closed at $6.61, down -0.15%. In other words, the price has decreased by -$0.15 from its previous closing price. On the day, 4.55 million shares were traded. RVNC stock price reached its highest trading level at $6.65 during the session, while it also had its lowest trading level at $6.6.
Ratios:
Our goal is to gain a better understanding of RVNC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.01 and its Current Ratio is at 3.74.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $16 previously.
On January 09, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $30 to $8.
Exane BNP Paribas Upgraded its Underperform to Neutral on August 16, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 16 ’24 when Jordan Erica sold 2,392 shares for $3.80 per share. The transaction valued at 9,096 led to the insider holds 114,864 shares of the business.
Sjuts Dustin S sold 9,211 shares of RVNC for $46,446 on Mar 18 ’24. The President now owns 167,550 shares after completing the transaction at $5.04 per share. On Mar 18 ’24, another insider, Moxie Dwight, who serves as the CLO & GC of the company, sold 8,125 shares for $5.04 each. As a result, the insider received 40,971 and left with 137,815 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RVNC now has a Market Capitalization of 689674176 and an Enterprise Value of 952274240. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.82. Its current Enterprise Value per Revenue stands at 3.791 whereas that against EBITDA is -4.958.
Stock Price History:
Over the past 52 weeks, RVNC has reached a high of $19.01, while it has fallen to a 52-week low of $2.30. The 50-Day Moving Average of the stock is 88.92%, while the 200-Day Moving Average is calculated to be 28.41%.
Shares Statistics:
The stock has traded on average 3.37M shares per day over the past 3-months and 11602140 shares per day over the last 10 days, according to various share statistics. A total of 104.18M shares are outstanding, with a floating share count of 94.97M. Insiders hold about 8.84% of the company’s shares, while institutions hold 83.51% stake in the company. Shares short for RVNC as of 1722384000 were 15647194 with a Short Ratio of 4.65, compared to 1719532800 on 15193716. Therefore, it implies a Short% of Shares Outstanding of 15647194 and a Short% of Float of 17.130000000000003.
Earnings Estimates
Current recommendations for the stock of the company come from 4.0 analysts. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.14 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.3 and -$1.57 for the fiscal current year, implying an average EPS of -$1.44. EPS for the following year is -$0.68, with 5.0 analysts recommending between -$0.46 and -$0.81.
Revenue Estimates
8 analysts predict $67.86M in revenue for the current quarter. It ranges from a high estimate of $73M to a low estimate of $56.8M. As of the current estimate, Revance Therapeutics Inc’s year-ago sales were $56.78MFor the next quarter, 8 analysts are estimating revenue of $88.48M. There is a high estimate of $96.2M for the next quarter, whereas the lowest estimate is $81.1M.
A total of 8 analysts have provided revenue estimates for RVNC’s current fiscal year. The highest revenue estimate was $281.49M, while the lowest revenue estimate was $266.5M, resulting in an average revenue estimate of $275.72M. In the same quarter a year ago, actual revenue was $234.04MBased on 8 analysts’ estimates, the company’s revenue will be $372.62M in the next fiscal year. The high estimate is $425.24M and the low estimate is $319.2M.
